Business
Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test's Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant
Toronto, Ontario--(Newsfile Corp. - December 16, 2021) - Therma Bright Inc. (TSXV: THRM) ("T...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test's Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 VariantToronto, Ontario--(Newsfile Corp. - December 16, 2021) - Therma Bright Inc. (TSXV: THRM) (\"Therma\" or the \"Company\"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to confirm that antibodies incorporated in its AcuVid™ COVID-19 Rapid Antigen Saliva Test have been tested and can successfully detect the new, highly transmissible COVID-19 Omicron B.1.1.529 variant.Ever since the SARS-CoV-2 Novel Coronavirus (COVID-19) became a global pandemic in early 2020, a variety of new variants have emerged, and the scientific community has worked tirelessly to evaluate each strain and its impact on the public's health. The Omicron B.1.1.529 variant, discovered in early November 2021 in South Africa and Botswana, has now become a growing global concern, and has been discovered in numerous countries around the world; including the United States, Canada, United Kingdom, and several Western and Eastern European nations. In fact, on December 3, 2021, the World Health Organization (WHO) confirmed the Omicron variant has been detected in at least 38 countries, and early data suggests it's more contagious than the Delta B.1.617.2 variant.1 The variant \"is spreading at a rate we have not seen with any previous variant,\" the head of WHO said. \"I need to be very clear: Vaccines alone will not get any country out of this crisis.\" 2To date, Therma Bright's AcuVid™ saliva test solution has successfully detected not only the original Wuhan SARS-CoV-2 Novel Coronavirus (COVID-19), but other WHO Variants of Concern, including the P.1 and P.2 variants discovered in Brazil, the B.1.1.7 variant from the UK, the highly contagious Delta B.1.617.2 variant from India and now the Omicron B.1.1.529 variant from the South Africa region.\"We're pleased to confirm that the antibodies incorporated in our saliva test have been tested and can successfully detect the Omicron variant,\" shared Rob Fia, CEO of Therma Bright. \"Now, as our partners finalize our U.S. AcuVid™ clinical performance study to submit to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA), our team is makin...